UltraSight, an Israeli company that makes AI software to guide clinicians through cardiac ultrasound scans, raised $24m in a Series B2 round on 23 September 2026. Alive HealthTech Growth Fund led the financing.
Deep Insight, Star51 Capital, Connecticut Innovations and eHealth Ventures joined as new investors, and existing backers Mayo Clinic Ventures, NYU and Iron Nation also took part. Calcalist's Ctech reported that the round brings UltraSight's total capital raised since its founding to $42m. The company did not disclose a valuation.
UltraSight said the money would fund commercial expansion of its platform across US health systems and the development of workflows for intensive care units and mechanical circulatory support settings.
“We are entering this next stage as our FDA-cleared portfolio continues to expand to support broader cardiac imaging workflows. This financing will help our efforts to translate that momentum into wider market adoption, deeper strategic collaborations and greater access to high-quality cardiac ultrasound – expediting care for patients who simply cannot afford to wait.”Davidi Vortman, CEO and Co-Founder, UltraSight
What UltraSight does
UltraSight's product, the Echosystem, combines real-time computer vision guidance, structured training and automated analytics. It is meant to let clinicians who are not trained sonographers, such as ICU nurses, hospitalists and emergency physicians, capture standard echocardiography views under a physician's oversight. The guidance software has FDA 510(k) clearance and uses on-screen prompts to direct the operator towards standard 2D echo views.
The company said the Echosystem is in use at more than 10 commercial sites, including intensive care settings. Interpretation and reporting of the images stay with physicians; the AI guides how the probe is handled rather than making a diagnosis.
In a study published in JAMA Cardiology on 28 August 2026, novice operators using UltraSight's guidance captured images that were then used for automated detection of moderate or worse aortic stenosis. The detection reached 93% sensitivity and 96% specificity, according to the company.
Who invested
Alive HealthTech Growth Fund did not disclose how much of the round it supplied. Alongside the financing, UltraSight appointed Rick Geoffrion, who has more than 30 years of experience in cardiovascular devices, as chairman of the board.
Three investor representatives also joined the board: Dudi Klein, co-founder and managing partner of Alive; Tal Wenderow, founding managing partner of Star51 Capital and co-founder of Corindus Vascular Robotics; and Barak Ben-Eliezer, managing partner of Deep Insight. The Mayo Clinic said in the announcement that it has a financial interest in the technology and would use any revenue it receives to support its not-for-profit mission.
Davidi Vortman, the company's chief executive and co-founder, said the financing would help translate the expansion of its FDA-cleared portfolio into wider adoption and more strategic collaborations.
The company so far
UltraSight was founded in 2018, originally as On-Sight Medical, by Itay Kezurer, Yaron Lipman and Achiau Ludomirsky, according to Ctech, which reported that the Rehovot-based company employs 25 people, 19 of them in Israel and the rest in the US.
In May 2021 the company raised $13m in a round Ctech described as a Series B, with participation from Yozma Group Korea, Atain Specialty Insurance Company and the Weizmann Institute of Science.
The company presents its model as a response to staffing shortages: by separating image capture from specialist sonography, it aims to let community hospitals and acute care units without round-the-clock sonographer cover perform cardiac scans when they are needed.
Company website: ultrasight.com